BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit- Remote Headphones: Improve Your Sound Insight
- A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Boats escort freed whale away from shallow waters off German coast
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- Mummified cheetahs found in Saudi caves shed light on lost populations
- Is 'Veronica Mars' about to be your new binge-watch? It's now streaming on Netflix.
